DYMDF (Diamyd Medical AB) Cyclically Adjusted Book per Share: $1.27 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DYMDF Diamyd Medical AB DYMDF
41 GF Score
Price $0.73
GF Value $9.89
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Cyclically Adjusted Book per Share?

Diamyd Medical AB DYMDF 41 Cyclically Adjusted Book per Share is $1.27 as of May. 2026. GuruFocus rates DYMDF with a GF Score™ of 41/100 and a GF Value™ of $9.89. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Diamyd Medical AB's adjusted book value per share for the three months ended in May. 2026 was $0.180. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.27 for the trailing ten years ended in May. 2026.

During the past 12 months, Diamyd Medical AB's average Cyclically Adjusted Book Growth Rate was 1.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -1.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Diamyd Medical AB was -1.70% per year. The lowest was -19.80% per year. And the median was -12.30% per year.

As of today (2026-08-10), Diamyd Medical AB's current stock price is $0.73. Diamyd Medical AB's Cyclically Adjusted Book per Share for the quarter that ended in May. 2026 was $1.27. Diamyd Medical AB's Cyclically Adjusted PB Ratio of today is 0.57.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Diamyd Medical AB was 16.65. The lowest was 0.52. And the median was 6.29.


Diamyd Medical AB  (OTCPK:DYMDF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Diamyd Medical AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.73/1.27
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Diamyd Medical AB was 16.65. The lowest was 0.52. And the median was 6.29.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Diamyd Medical AB Cyclically Adjusted Book per Share Related Terms


Diamyd Medical AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Cyclically Adjusted Book per Share Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.24 0.36 0.20 0.12

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.12 0.14 0.10 1.27

DYMDF vs VRTX, REGN, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted PB Ratio falls into.


DYMDF
41GF Score
Diamyd Medical AB DYMDF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Diamyd Medical AB's adjusted Book Value per Share data for the three months ended in May. 2026 was:

Adj_Book= Book Value per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0.18/134.1100*134.1100
=0.180

Current CPI (May. 2026) = 134.1100.

Diamyd Medical AB Quarterly Data

Book Value per Share CPI Adj_Book
201608 0.100 100.968 0.133
201611 0.093 101.517 0.123
201702 0.070 102.037 0.092
201705 0.030 102.679 0.039
201708 0.185 103.138 0.241
201711 0.161 103.413 0.209
201802 0.143 103.678 0.185
201805 0.107 104.632 0.137
201808 0.082 105.197 0.105
201811 0.065 105.443 0.083
201902 0.122 105.641 0.155
201905 0.106 106.895 0.133
201908 0.091 106.716 0.114
201911 0.082 107.345 0.102
202002 0.135 106.742 0.170
202005 0.124 106.882 0.156
202008 0.117 107.571 0.146
202011 0.296 107.549 0.369
202102 0.333 108.190 0.413
202105 0.352 108.838 0.434
202108 0.296 109.780 0.362
202111 0.421 111.069 0.508
202202 0.388 112.834 0.461
202205 0.341 116.746 0.392
202208 0.261 120.573 0.290
202211 0.214 123.803 0.232
202302 0.189 126.321 0.201
202305 0.169 128.034 0.177
202308 0.182 129.560 0.188
202311 0.207 130.958 0.212
202402 0.182 132.046 0.185
202405 0.182 132.818 0.184
202408 0.140 132.052 0.142
202411 0.137 133.000 0.138
202502 0.099 133.744 0.099
202505 0.244 133.064 0.246
202508 0.213 133.440 0.214
202511 0.177 133.340 0.178
202602 0.137 134.410 0.137
202605 0.180 134.110 0.180

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.27 mean?
Diamyd Medical AB (DYMDF) has a Cyclically Adjusted Book per Share of $1.27 as of May. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's Cyclically Adjusted Book per Share too high?
Diamyd Medical AB's current Cyclically Adjusted Book per Share is $1.27. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Diamyd Medical AB's Cyclically Adjusted Book per Share of $1.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Cyclically Adjusted Book per Share is $1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current Cyclically Adjusted Book per Share of $1.27. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is $1.27. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current Cyclically Adjusted Book per Share is $1.27 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (DYMDF) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued. The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.

Key valuation signals for DYMDF:

  • Cyclically Adjusted Book per Share: $1.27
  • GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diamyd Medical AB Business Description

Other Exchanges DMYD B:SwedenDMN:Germany
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for DYMDF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price
$9.89
GF Value